GlobeNewswire by notified

Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox

Share

COPENHAGEN, Denmark, July 25, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX® to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway.

The label extension was approved after submission of a rolling type-II variation application in June 2022, in alignment between Bavarian Nordic and the European Medicines Agency’s Emergency Task Force (ETF), Rapporteurs and the European Health Emergency Preparedness and Response Authority (HERA). The EC approved the full IMVANEX indication as: Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults. The monkeypox indication approval is an example of great cooperation between Bavarian Nordic and the European regulators as such an indication extension normally takes at least 6-9 months to achieve.

Paul Chaplin, President and CEO of Bavarian Nordic said: “We are pleased to receive the approval from the European Commission, broadening the label of our vaccine to include monkeypox. The availability of an approved vaccine can significantly improve nations’ readiness to fight emerging diseases, but only through investments and structured planning of the biological preparedness. The development of IMVANEX was made possible through significant investments from the U.S. government for the past two decades, leading the way for other governments to develop plans and prioritize for the future to protect their citizens against public health threats. With this approval, we look forward to working closer with the EU and its member states to solve this important task.”

About IMVANEX®
IMVANEX® (MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada (marketed as IMVAMUNE®) and the U.S. (marketed as JYNNEOS®) where the approvals have been extended to include the monkeypox indication as the only vaccine having obtained this to-date.

Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, smaller quantities of the vaccine have been supplied in response to sporadic cases of monkeypox. During the ongoing 2022 outbreak of monkeypox, Bavarian Nordic has worked with several governments to fulfil the immediate demand for the vaccine through a number of supply agreements and is working to secure manufacturing of vaccines to fulfil the demand in the medium- to long term.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Notice of Nexstim Plc’s Half-Yearly Report H1 20228.8.2022 09:00:00 CEST | Press release

Companyannouncement,Helsinki,8 August2022at10 AM(EEST) Noticeof NexstimPlc’sHalf-Yearly Report H1 2022 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2022 on Friday 12 August 2022 at approximately 9:00 am Finnish time. The company will hold two live webinars for media, investors and analysts on Friday 12 August 2022. Mikko Karvinen CEO, and Joonas Juokslahti CFO, will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish, and it will take place at 10:30 am EEST. The second live webinar will be in English at 3 pm EEST. Webinardetails: To attend the webinars, please register via the links below. Registered participants will receive more information to their e-mail. Live Webinar in Finnish on 12 August 2022 at 10:30 am (EEST): Sign up here >> Live Webinar in English on 12 August 2022 at 3 pm (EEST): Sign up here >> NEXSTIM PLC Mikko Karvinen, CEO F

Publicering av Nexstim Abp:s halvårsrapport för H1 20228.8.2022 09:00:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors,8augusti2022 kl.10(EEST) Publicering av Nexstim Abp:s halvårsrapport för H1 2022 Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) kommer att meddela sitt halvårsresultat för det gångna halvåret som avslutades den 30 juni 2022, på fredagen den 12 augusti 2022 cirka kl. 9.00 finsk tid. Bolaget ordnar två webbsända möten för analytiker, investerare och medier fredagen 12 augusti 2022. Verkställande direktör Mikko Karvinen och ekonomichef Joonas Juokslahti presenterar det finansiella resultatet och rörelseresultatet verifier deltagarna ges möjlighet att ställa frågor. Den första webbsändningen på finska börjar klockan 10.30 (EEST). Den andra webbsändningen på engelska börjar klockan 15.00 (EEST). Uppgifteromwebbsändningarna: Anmälning till webbsändningarna sker via länkarna nedan. De deltagare som anmält sig får närmare anvisningar per e-post. Webbsänt informationsmöte på finska 12 augusti 2022 klockan 10.30 (EEST): Till anmälan >> Webbsänt info

Sampo plc’s share buybacks 05/08/20228.8.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 08/08/2022 at 08:30 am Sampo plc’s share buybacks 05/08/2022 On 05/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,33944.37AQEU14,45644.38CEUX7,48944.42TQEX78,18844.36XHELTOTAL114,47244.37 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 5,603,062 Sampo A shares representing 1.05 per cent of the total number of shares in Sampo plc. Details of ea

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS5.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-09BondsKOMMUNINVEST I SVERIGE: 2602. SE0013745452. 2026-02-04 KOMMUNINVEST I SVERIGE: 2706, SE0016829048, 2027-06-15 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2022-08-09Bid times10.00-11.00Requested volume (corresponding nominal amount)2602: 200 mln SEK +/-100 mln SEK 2706: 200 mln SEK +/-100 mln SEK Highest permitted bid volume (corresponding nominal amount)2602: 200 mln SEK per bid 2706: 200 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-11Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020 (see the Riksbank´s web). Stockholm, 2022-08-05 This i

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS5.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-11BondsSWEDBANK HYPOTEK AB: 197. SE0016828529. 2027-03-17 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 DANSKE HYPOTEK AB: 2612, SE0015987540, 2026-12-16 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 Bid date2022-08-11Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)197: 200 mln SEK +/-100 mln SEK 581: 200 mln SEK +/-100 mln SEK 2612: 100 mln SEK +/-50 mln SEK 5535: 150 mln SEK +/-100 mln SEK Highest permitted bid volume (corresponding nominal amount)197: 200 mln SEK per bid 581: 200 mln SEK per bid 2612: 100 mln SEK per bid 5535: 150 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-15Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-08-05 This is a translation of the special terms and